PMC:7696151 / 69510-69824
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1974 | 60-68 | Species | denotes | patients | Tax:9606 |
| 1993 | 137-147 | Chemical | denotes | infliximab | MESH:D000069285 |
| 2001 | 74-103 | Disease | denotes | juvenile idiopathic arthritis | MESH:D001171 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T128 | 74-103 | Phenotype | denotes | juvenile idiopathic arthritis | http://purl.obolibrary.org/obo/HP_0005681 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T443 | 0-314 | Sentence | denotes | In a multicenter open-label clinical trial, performed on 60 patients with juvenile idiopathic arthritis for 54 weeks, the combination of infliximab monoclonal antibodies with a conventional antirheumatic drug provided the better response in terms of disease inactivation with respect to DMARD administration [128]. |